EXCLUSIVE: BlinkRx rips “baseless smear” linking company to TrumpRx
BlinkRx pushed back on smears pushed by top congressional Democrats in a letter obtained exclusively by the Washington Reporter.
BlinkRx is a digital pharmacy platform that partners with leading manufacturers, specialists, and health-systems that has become one of the fastest-growing patient-access companies in the country. Known for helping millions of Americans secure affordable medications through a streamlined, tech-driven process, the company has earned a strong reputation.
Recently, Congressional Democrats launched an attack against BlinkRx, accusing the company of helping design President Donald Trump’s initiative to lower drug costs.
Now, BlinkRx is pushing back hard and setting the record straight.
In a letter obtained exclusively by the Washington Reporter and sent to Sen. Ron Wyden (D., Or) and Reps. Frank Pallone (D., N.J.) and Richard Neal (D., Mass.), BlinkRx’s Vice President and Special Counsel Drew Hudson stated that BlinkRx first learned about TrumpRx “from press reports” and had “no role in the development” of the announcement.
The Democrats’ late-October inquiry insinuated BlinkRx played a behind-the-scenes role in crafting TrumpRx. The Democrats had no evidence for this.
A senior Senate Republican aide blasted the Democrats’ effort as “a desperate attempt to manufacture a scandal where none exists.”
“BlinkRx is a respected, innovative company that has helped millions of Americans afford their medications. Democrats tried to kneecap them simply because Trump is in the picture,” the aide told the Reporter. “They picked the wrong target, and their smear fell apart on contact with the facts.”
The company further dismantled Democrats’ efforts to cast TrumpRx as partisan. BlinkRx highlighted that the Trump administration has engaged numerous pharmacies, retailers, and discount-card platforms — including billionaire Mark Cuban’s Cost Plus Drugs. Cuban famously campaigned for Kamala Harris in 2024, yet he publicly announced he would participate in the Trump program.
Privately, GOP staff say the Democrats’ letter was more about generating press clips than it was about conducting oversight. “This was never a serious inquiry,” the Senate aide added. “It was a press stunt — and BlinkRx just blew it up.”
BlinkRx concluded its letter by reaffirming its commitment to work with policymakers of any party to lower costs and improve transparency, but made clear it will not let its reputation be used as a prop in a manufactured controversy.